Aug 20, 2026 07:04AM
Aug 20, 2026 07:00AM
Aug 10, 2026 04:05PM
Aug 6, 2026 07:00AM
Aug 6, 2026 07:00AM
Jul 20, 2026 08:00AM
Jul 20, 2026 08:00AM Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026
Jul 20, 2026 07:01AM
Jul 20, 2026 07:00AM
Jul 1, 2026 07:00AM
Jul 1, 2026 07:00AM
Jul 1, 2026 07:00AM
Jul 1, 2026 07:00AM
Jun 10, 2026 07:01AM Harrow re-launches VERKAZIA eye drops for pediatric eye condition
Jun 10, 2026 07:00AM
May 11, 2026 04:05PM
Apr 16, 2026 07:00AM
Mar 19, 2026 06:59AM
Mar 18, 2026 07:00AM
Mar 3, 2026 03:15PM
Mar 3, 2026 07:02AM Harrow begins phase 3 trial for TRIESENCE in cataract surgery patients
Mar 3, 2026 07:00AM
Mar 2, 2026 04:05PM
Feb 17, 2026 07:00AM
Feb 3, 2026 05:00AM
Nov 18, 2025 07:01AM
Nov 18, 2025 07:00AM
Nov 10, 2025 04:05PM Harrow Announces Third Quarter 2025 Financial Results
Oct 6, 2025 07:00AM
Oct 6, 2025 07:00AM
Sep 26, 2025 07:00AM
Sep 26, 2025 07:00AM
Sep 23, 2025 06:45AM
Aug 11, 2025 04:01PM
Jul 17, 2025 07:00AM Harrow secures exclusive US rights to Samsung Bioepis eye biosimilars
Jul 17, 2025 07:00AM
Jul 17, 2025 07:00AM
Jun 11, 2025 04:25PM
Jun 9, 2025 07:03AM
Jun 9, 2025 07:00AM
May 8, 2025 04:01PM
Apr 10, 2025 07:00AM Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients
Mar 27, 2025 04:01PM
Mar 24, 2025 07:05AM
Mar 24, 2025 07:00AM
Mar 11, 2025 07:00AM
Feb 6, 2025 08:44AM
Jan 7, 2025 07:01AM
Jan 7, 2025 07:00AM Harrow Appoints Amir H. Shojaei as Chief Scientific Officer
Nov 22, 2024 01:51PM

330,713 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All